Azaquinolone Compounds for Selective PARP1 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet medical need for effective and safe PARP inhibitors, particularly those with selectivity for PARP1, to treat cancers and conditions involving the central nervous system, and existing PARP inhibitors often have toxicity issues and lack specificity for PARP1.
Innovation Solution
Development of azaquinolones with high selectivity for PARP1 over other PARP family members and the ability to penetrate the blood-brain barrier, offering therapeutic benefits for various cancers and CNS conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing PARP inhibitors are used to treat cancers, then PARP inhibition activity is achieved, but toxicity increases and selectivity for PARP1 is reduced
Solution Approach 1:
The patent applies local quality by designing the azaquinolone compound with specific substituent patterns at different positions (R1-R6) to create localized interactions with PARP1. The compounds feature specific functional groups at particular positions that enhance binding to PARP1's unique structural features, thereby achieving selective inhibition of PARP1 while sparing other PARP family members, which reduces off-target toxicity.
Solution Approach 2:
The patent employs parameter changes by systematically varying the chemical structure of the core azaquinolone scaffold through different substituents (halogens, alkyl groups, heterocycles) to optimize the balance between PARP1 binding affinity and selectivity. By adjusting parameters such as substituent type, position, and stereochemistry, the compounds achieve enhanced PARP1 inhibition with reduced cross-reactivity to other PARPs, thereby lowering toxicity.
2Reliability
If existing PARP inhibitors are used, then broad PARP family inhibition is achieved, but selectivity for PARP1 is reduced
Solution Approach 1:
The azaquinolone compounds incorporate specific local structural features (such as substituents at R2, R4, and R6 positions) that create localized binding interactions with unique residues in PARP1's active site. These localized interactions enhance discrimination between PARP1 and other PARP family members, achieving high selectivity while maintaining inhibition activity.
Solution Approach 2:
The patent utilizes asymmetry by introducing chiral centers and asymmetric substituent patterns on the azaquinolone core. The compounds feature specific stereochemical configurations (e.g., (R) or (S) enantiomers) that create asymmetric binding modes with PARP1, enhancing selectivity through stereospecific interactions that are not accommodated by other PARP isoforms.
3Reliability
If azaquinolones are designed for CNS penetration, then BBB penetration is achieved, but molecular complexity increases
Solution Approach 1:
The patent applies parameter changes by optimizing key molecular properties including molecular weight (keeping it moderate), lipophilicity (through balanced hydrophobic/hydrophilic substituents), and hydrogen bonding capacity. These parameter adjustments enable the azaquinolone compounds to traverse the blood-brain barrier effectively without requiring overly complex molecular structures.
Solution Approach 2:
The azaquinolone core structure serves multiple functions simultaneously: it provides the essential PARP1 binding pharmacophore, accommodates various substituents for optimizing BBB penetration, and maintains adequate solubility. This multi-functionality allows a single molecular scaffold to achieve both therapeutic efficacy and CNS penetration without excessive complexity.
Data Source
AI summary
The present invention relates to azaquinolone compounds of Formula (I), and their use in medicine.